UNSPSC 51241131: Brimonidine tartrate

This classification denotes an alpha-adrenergic agonist with the molecular formula C11H10BrN5.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4S9CL2DY2H, chemically known as 6-quinoxalinamine, 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)- (9ci) but generally known as brimonidine tartrate, which bears US NIH Compound Identifier 2435. European Medicines Agency schedules Brimonidine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13122MIG.

Most nations schedule brimonidine tartrate under HS 29332990 and SITC 51573. As of Q4 2014, BRIMONIDINE TARTRATE remains the US FDA Preferred Term for this commodity. Brimonidine tartrate bears US NLM identifiers UMLS ID C0077768 and NCI Concept Code C47419. SMILES: C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.C(C(C(=O)O)O)(C(=O)O)O.

UNSPSC 51241131 Brimonidine tartrate is a Commodity code representing a specific pharmaceutical active ingredient procured by state and local health agencies, primarily through state Medicaid programs, public health departments, and corrections facilities. Brimonidine tartrate is an alpha-2 adrenergic agonist used topically to treat glaucoma and ocular hypertension, and systemically in some formulations for attention-deficit/hyperactivity disorder; state and local governments purchase this drug as part of pharmacy benefit management, inmate healthcare, and public health clinic operations. Issuing bodies under this code are typically state health departments administering Medicaid pharmacy programs, county health systems, and state corrections departments procuring through centralized pharmaceutical contracts or cooperative purchasing arrangements. Activity is driven by formulary adoption decisions, medication-therapy management protocols, and budget cycles rather than by individual project RFPs.

The source provided contains no recent state and local contract opportunities tagged to this code. Without posted solicitations, RFQ records, or cooperative purchasing vehicle listings in the data block, no geographic concentration, issuing-body repeat patterns, or representative opportunities can be identified. Brimonidine tartrate procurement at the state and local level typically occurs through standing pharmaceutical supply contracts, state Medicaid preferred-drug lists, and group purchasing organization (GPO) memberships negotiated at the state level rather than through individual posted competitive notices, which may explain the absence of visible opportunities in the public solicitation record.